Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

AACR 2021

10 Apr - 21 May 2021

Virtual

Rare inherited pathogenic germline variants observed in sporadic paediatric...

Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA

Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases ( Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA )

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA...

Dr Matthew Marx - Mirati Therapeutics, San Diego, USA

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients...

Prof Ravi Salgia - City of Hope, Duarte, USA

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers ( Prof Ravi Salgia - City of Hope, Duarte, USA )

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as...

Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC ( Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA )

Phase III randomised trial comparing tebentafusp with investigator’s choice in...

Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in...

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )

Healthy lifestyle may offset risk of lethal prostate cancer in men with high...

Dr Anna Plym - Harvard University, Boston, USA

Healthy lifestyle may offset risk of lethal prostate cancer in men with high genetic risk ( Dr Anna Plym - Harvard University, Boston, USA )

SMMART Program: A multi-omics tumour board with a focus on breast cancer

Dr Ben Kong - Oregon Health & Science University, Portland, USA

SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )

PC14586: The first orally bioavailable small molecule reactivator of Y220C...

Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in...

Prof Georgina Long - University of Sydney, Sydney, Australia

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Clinical validation of a targeted methylation-based multi-cancer early...

Dr Eric Klein - Cleveland Clinic, Cleveland, USA

Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )

Safety and efficacy of atezolizumab plus bevacizumab for unresectable...

Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than...

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

High-quality neoantigens are immunoedited in long-term survivors of pancreatic...

Prof Marta Luksza - Tisch Cancer Institute, New York, USA

High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer ( Prof Marta Luksza - Tisch Cancer Institute, New York, USA )

More from ecancer